CAI · Caris Life Sciences, Inc.
$30.39
+2.09 (+7.39%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$8.92B
Shares
282.60M
Volume · Oct 5
4.88M
Avg daily vol (3M)
4.83M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$28.30
Open$28.72
Day$28.07–28.97
52W close$14.55–32.95
Avg vol 30d5.3M
Short int13.3M · 4.7% float · 3.0d
Short vol53%
Last earningsAug 5, 2026
DataJun 2025–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 1, 2026
Est · unconfirmed
· in 4 wks
filed Aug 5, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$989.61M
Trailing 12 months
Net income (TTM)
$105.14M
Trailing 12 months
Revenue growth YoY
+45.4%
Year over year
Operating margin
15.5%
Trailing 12 months
P / E (TTM)
3.4
Trailing earnings · reciprocal yield 29.4%
FCF yield
1.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$440.64M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+335.8%
Year over year · more shares
Price change (1Y)
-4.7%
Trailing year
Short interest
4.7%
Latest settlement · 3.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+33%
above
Price vs 50-day avg
+16%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
75%
mid-range
Momentum
relative strength
1-month return
+12%
trailing
6-month return
+48%
trailing
YTD return
+5%
this year
Relative strength
+36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $24 › 200d $21 — 50d above 200d
Institutional flow
Accumulating
2 of 248 funds reported for Sep 30 · net +9.7K sh shares · +1 new
Insider flow
Distributing
Net -$27.2M over 90 days · 100% sells
Short interest
Falling
4.72% of float · ▼ -2.6% MoM · 3.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
248 holders — near 1-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+97%
Y/Y
EPS growth
+70%
Y/Y
Free cash flow
$66.9M
Valuation
P/E 84.8
rich
Buyback
$82.1M
remaining
Balance sheet
$417.3M
net cash
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−56%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Total revenue
· full year 2026
Initiated
$1.03B – $1.04B
prior FY $812.03M
midpoint +27.5% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+33%
Bullish
Price vs 50-day avg
+16%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
75%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $24 › 200d $21 — 50d above 200d
Institutional flow
Accumulating
2 of 248 funds reported for Sep 30 · net +9.7K sh shares · +1 new
Insider flow
Distributing
Net -$27.2M over 90 days · 100% sells
Short interest
Falling
4.72% of float · ▼ -2.6% MoM · 3.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
248 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $15
Now $28 · 75%
Range high $33
vs 200-day avg +33%
vs 50-day avg +16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $55.7M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss -637K
-6.82M Interest income
+9.23M Interest expense
+0K Changes in fair value of financial instruments
+25.13M Other expense, net
+23K Income tax expense (benefit)
+6.54M Depreciation and amortization expense
+22.22M Stock-based compensation expense
= Adjusted EBITDA 55.68M
|
|||
| Caris Assure cases | 10,700 | Q2 2026 | — |
| Clinical cases | 59,200 | Q2 2026 | +18.4% |
|
|
|||
| Free cash flow non-GAAP | $6.4M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by (used in) operating activities 28.48M
-22.08M Less: capitalized software and purchases of property and equipment
= Free cash flow 6.4M
|
|||
| MI Profile cases | 48,300 | Q2 2026 | — |
| Revenue from clinical cases for patients covered by Medicare | 38.9% | the three months ended June 30, 2026 filing | — |
| Share repurchase program (remaining authorization) | $82.1M | as of August 5, 2026 | — |
| Total matched profiles | 845,000 | through June 30, 2026 | — |
| Total oncology tests | 345,000 | Q2 2026 | — |
| Total profiles | 1,130,000 | through June 30, 2026 | — |
| Whole exome profiles | 733,000 | through June 30, 2026 | — |
| Whole exome/whole transcriptome tests | 114,000 | Q2 2026 | — |
| Whole transcriptome profiles | 783,000 | through June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CAI
this stock
Caris Life Sciences, Inc.
|
$8.92B | +4.9% | +97.0% | 84.8 | 4.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CAI | -11.5% | +11.8% | +47.9% | -7.6% | +4.9% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -11.3% | +12.2% | +35.8% | -8.5% | -8.0% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$100.00M
Spent (derived)
$17.90M
Remaining
$82.10M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.